Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma

Leukemia

Volumn 22, Issue 8, 2008, Pages 1595-1603

  Dien Bard, J ^a   Gelebart, P ^a   Anand, M ^a   Amin, H M ^b   Lai, R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BINDING PROTEIN; HYBRID PROTEIN; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 10 RECEPTOR 2; INTERLEUKIN 22; INTERLEUKIN 22 BINDING PROTEIN; INTERLEUKIN 22 NEUTRALIZING ANTIBODY; INTERLEUKIN 22 RECEPTOR 1; INTERLEUKIN RECEPTOR; NEUTRALIZING ANTIBODY; NUCLEOPHOSMIN; ONCOPROTEIN; PROTEIN NPM ALK; SMALL INTERFERING RNA; STAT3 PROTEIN;

ANAPLASTIC CARCINOMA; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 49449100887     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.129     Document Type: Article

References (40)

1. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
2. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: Multiple levels of leukocyte migration control. Trends Immunol 2004; 25: 75-84.
3. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994; 9 1567-1574.
4. Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001; 61: 2194-2199.
5. Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004; 23: 5426-5434.
6. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002; 21: 1038-1047.
7. Bromberg JF, Wrzeszczynska MH, Pevgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295-303.
8. Burke WM, Jin X, Lin HJ, Huang M, Liu R, Reynolds RK et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001; 20: 7925-7934.
9. Catlett-Falcone RLT, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G et al. Constitutive activation of Stat3 signaling cofers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115.
10. Levy DE, Lee CK. What does Stat3 do? J Clin Invest 2002; 109 1143-1148.
11. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R et al. Stat3 is required for ALK-mediated lymohomagenesis and provides a possible therapeutic target. Nat Med 2005; 11: 623-629.
12. Amin HM, Medeiros LJ, Ma Y, Feretzaki M, Das P, Leventaki V et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 2003; 22: 5399-5407.
13. Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW et al Nucleophosmin-anaplastic lymphoma kitiase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 2004; 103: 1464-1471.
14. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosminanaplastic lymphoma kinase (NPM-ALK) a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res 2002; 62: 1559-1566.
15. Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 2000; 164: 1814-1819.
16. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: Immune cells as sources and targets of the IL-10 family members? J Immunol 2002; 168: 5397-5402.
17. Wolk K, Witte E, Reineke U, Witte K, Friedrich M, Sterry W et al. Is there an interaction between interleukin-10 and interleukin-22? Genes Immun 2005; 6: 8-18.
18. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: A potential role in psoriasis. Eur J Immunol 2006; 36: 1309-1323.
19. Dumoutier L, Lejeune D, Colau D, Renauld JC. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 2001; 166: 7090-7095.
20. Gruenberg BH, Schoenemeyer A, Weiss B, Toschi L, Kunz S, Wolk K et al A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta. Genes Immun 2001; 2: 329-334.
21. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP et al. Identification of the functional interleukin-22 (IL-22) receptor complex: The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 2001; 276: 2725-2732.
22. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002; 277: 33676-33682.
23. Gurney AL. IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int Immunopharmacol 2004; 4: 669-677.
24. Lamant L, De Reynies A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S et al. Gene expression profiling of systemic anaplastic large cell lymphoma reveals differences depending on ALK status and two distinct morphological ALK+ subtypes. Blood 2007: 109: 2156-2164.
25. Dien J, Amin HM, Chiu N, Wong W, Frantz C, Chiu B et al. Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol 2006; 169: 633-642.
26. Han Y, Amin HM, Frantz C, Franko B, Lee J, Lin Q et al. Restoration of shp1 expression by 5-AZA-2′-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia 2006; 20: 1602-1609.
27. Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 2000; 275: 31335-31339.
28. Kotenko SV. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev 2002; 13: 223-240.
29. Brand S, Dambacher J, Beigel F, Zitzmann K, Heeg MH, Weiss TS et al IL-22 mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1019-G1028.
30. Weber GF, Gaertner FC, Erl W, Janssen KP, Blechert B, Holzmann B et al. IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 2006; 177: 8266-8272.
31. Nagalakshmi ML, Rascle A, Zurawski S, Menon S, de Waal Malefyt R. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 2004; 4: 679-691.
32. Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 2006; 108 2796-2803.
33. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007; 110: 2259-2267.
34. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 2002; 168: 466-474.
35. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005; 129: 969-984.
36. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K et al Expression of interleukin-22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. Arthritis Rheum 2005; 52: 1037-1046.
37. Du L, Lyle CS, Obey TB, Gaarde WA, Muir JA, Bennett BL et al. Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: Evidence that mitotic Bcl-2 phosphorylation is JNK-independent. J Biol Chem 2004; 279: 11957-11966.
38. Nagata Y, Todokoro K. Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. Blood 1999; 94: 853-863.
39. Ono K, Han J. The p38 signal transduction pathway: Activation and function. Cell Signal 2000; 12: 1-13.
40. Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene 2007; 26: 813-821.